Editorial Board About Us

Alan W Partin

All articles from this author are listed below.

Volume 11, Number 3 Literature Reviews

Prostate Cancer

News and Views From the Literature

Stacy Loeb Alan W Partin

Volume 11, Number 2 Literature Reviews

Prostate Cancer

News and Views From the Literature

Stacy Loeb Alan W Partin

[Rev Urol. 2009;11(2):114-115]

Volume 11, Number 2 Meeting Reviews

Best of the 2009 AUA Annual Meeting

Highlights From the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL

Claus G Roehrborn Stacy Loeb J Curtis Nickel Michael K Brawer Naoki Yoshimura Arie S Belldegrun B Shuch F Pouliot Alan W Partin Ellen Shapiro Dean G Assimos Michael B Chancellor

Prostate cancer screening Obesity Benign prostatic hyperplasia Lower urinary tract symptoms Vesicoureteral reflux Nephrolithiasis Stress urinary incontinence Inflammation Silodosin Hormonal therapy Tumor markers TMPRSS2ERG 4-Kallikrein panel Botulinum toxin type A Male voiding dysfunction Benign prostatic specific antigen Roux-en-Y gastric bypass surgery Genitourinary pain index UPOINT clinical phenotype system Nephron-sparing surgery Watchful waiting Laparoscopy for adrenal cortical carcinoma Partial adrenalectomy Urethral trauma Pediatric urethral stricture Enteric urologic surgery

Volume 11, Number 1 Review Articles

Robotic Image-Guided Needle Interventions of the Prostate

Technology Update

Pierre C Mozer Dan Stoianovici Alan W Partin

Prostate biopsy and needle-directed prostate therapies are currently performed free-handed or with needle external templates under ultrasound guidance. Direct image-guided intervention robots are modern instruments that have the potential to substantially enhance these procedures. These may increase the accuracy and repeatability with which needles are placed in the gland. The authors’ group has developed a robot for precise prostate targeting that operates remotely alongside the patient in the magnetic resonance imaging scanner, as guided according to the image.[Rev Urol. 2009;11(1):7-15]

Prostate Robot Direct image-guided intervention (DIGI)MRI compatible

Volume 12, Number 4 Literature Reviews

PCA3 Urinary Biomarker for Prostate Cancer

Prostate Cancer

Stacy Loeb Alan W Partin

[Rev Urol. 2010;12(4):e205-e206 doi: 10.3909/riu0507]© 2010 MedReviews®, LLC

Volume 12, Number 1 Review Articles

Complications of Pelvic Lymphadenectomy: Do the Risks Outweigh the Benefits?

Treatment Review

Stacy Loeb Alan W Partin Edward M Schaeffer

The American Urological Association Best Practice Policy states that although pelvic lymph node dissection (PLND) is commonly done with radical prostatectomy, its morbidity must be considered, particularly in cases in which it offers little additional information. The benefits of PLND include more accurate staging and reassurance for the patient. In addition, PLND may be therapeutic for men with lymph node metastases and may result in long-term biochemical cure for selected node-positive patients. However, the incidence of node positivity is declining, and accordingly a greater number of lymphadenectomies must be performed to benefit 1 patient. In addition to the associated cost, PLND has the potential for morbidity, including lymphoceles, thromboembolic events, ureteral injury, and neurovascular injury. Patients and physicians should therefore assess the risk/benefit ratio associated with PLND on an individual basis to permit informed treatment decisions.[Rev Urol. 2010;12(1):20-24 doi:10.3909/riu0422]

Prostate cancer Radical prostatectomy Pelvic lymph node dissection Ureteral injury Lymph node metastases Risk to benefit ratio Lymphocele Thromboembolic events Vascular injury Nerve injury

Volume 12, Number 1 Literature Reviews

Prostate Cancer

Reviewing the Literature

Stacy Loeb Alan W Partin

Volume 13, Number 4 Review Articles

Review of the Literature: PCA3 for Prostate Cancer Risk Assessment and Prognostication

Diagnosis Review

Alan W Partin Stacy Loeb

Prostate cancer antigen 3 (PCA3) is a novel urine-based prostate cancer biomarker that has recently been studied extensively for the prediction of prostate biopsy results and treatment outcomes. Numerous studies have demonstrated that urinary PCA3 scores are predictive of prostate cancer detection on both initial and repeat biopsy. There is conflicting evidence on the relationship between PCA3 with aggressive tumor features and treatment outcomes. This article reviews the current evidence on PCA3 as a marker for prostate cancer detection and prognosis. [Rev Urol. 2011;13(4):e191-e195 doi: 10.3909/riu0539] © 2011 MedReviews®, LLC

Prostate cancer Prostatectomy Prostate cancer antigen 3 Risk assessment

Volume 13, Number 1 Literature Reviews

Imaging Utilization for the Staging of Clinically Localized Prostate Cancer

Prostate Cancer

Alan W Partin Stacy Loeb

[Rev Urol. 2011;13(1):63-64 doi: 10.3909/riu0518]

Hydronephrosis Renal colic Appendicitis Abscess